GITNUX MARKETDATA REPORT 2024
Hyperhidrosis Treatment Industry Statistics
The global hyperhidrosis treatment industry is expected to experience steady growth due to increasing awareness and demand for treatment options.
In the following post, we will explore key statistics and insights regarding the global hyperhidrosis treatment industry, shedding light on market trends, prevalence rates, treatment options, leading players, and more. From the market size to regional dynamics and innovative therapies, this analysis provides a comprehensive overview of an industry addressing a common yet often overlooked condition.
Statistic 1
"The global hyperhidrosis treatment market size was valued at nearly USD 2 billion in 2021."
Statistic 2
"North America held the largest share of the market in 2020."
Statistic 3
"The Asia Pacific is projected to witness the fastest CAGR over the forecast period."
Statistic 4
"The disease prevalence is higher in young adults and middle-aged people."
Statistic 5
"The high prevalence of secondary generalized hyperhidrosis and a strong product line are driving the market."
Statistic 6
"The high cost of treatment is a major factor restraining market growth."
Statistic 7
"The notable players in the market include Allergan, GlaxoSmithKline plc, Revance Therapeutics, Inc., and Ulthera, Inc."
Statistic 8
"Pharmaceutical treatment is the largest product category in the market."
Statistic 9
"The iontophoresis segment is expected to exhibit the highest growth rate."
Statistic 10
"The estimated prevalence of axillary hyperhidrosis (underarm sweating) is about 1.4% of the U.S. population."
Statistic 11
"Approximately 75% of patients with hyperhidrosis have not been diagnosed and are not receiving treatment."
Statistic 12
"Botox (OnabotulinumtoxinA) is a common treatment option that reduces sweating by 82-87% approximately a week following treatment."
Statistic 13
"More than half of people with hyperhidrosis have not discussed their condition with a healthcare provider."
Statistic 14
"Drug class non-invasive/non-drug therapies, including iontophoresis and microwave thermolysis, accounted for the significant share of the market in 2020."
Statistic 15
"The primary hyperhidrosis segment dominated the market in 2020 based on disease type."
Statistic 16
"Topical treatments, including aluminum chloride and glycopyrrolate, are generally the first line of defense against hyperhidrosis."
Statistic 17
"ETS surgery is a permanent procedure that is only recommended for severe cases of hyperhidrosis."
Jannik Lindner
Can You Trust Our Report?
The statistics are checked by us and then entered into the database. Our market data reports have been linked to by some of the largest publishers and companies on the Internet.
